University of California, Los Angeles

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 1919-05-23

Employees: 10K

Market Cap: -

Website: http://www.ucla.edu

Clinical Trials

Behavioral Therapy Development for Methamphetamine Abusers

Phase 2

Withdrawn

Conditions: The Study Was Designed to Develop a Cognitive Behavioral Approach to Treating Methamphetamine Abuse in HIV Primary Care Settings

First Posted Date: 2005-11-07

Last Posted Date: 2020-02-17

Lead Sponsor: University of California, Los Angeles

Registration Number: NCT00249678

Locations: 🇺🇸
UCLA CARE Clinic, Los Angeles, California, United States
🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸
UCLA, Integrated Substance Abuse Programs, Los Angeles, California, United States

Gender-Responsive Treatment for Women Offenders - 1

Not Applicable

Completed

Conditions: Substance Abuse Problem

Interventions: Behavioral: Women-Only

First Posted Date: 2005-11-07

Last Posted Date: 2014-04-07

Lead Sponsor: University of California, Los Angeles

Target Recruit Count: 291

Registration Number: NCT00249613

Locations: 🇺🇸
University of California - Los Angeles, Los Angeles, California, United States

Study to Evaluate the Efficacy of Botulinum Toxin Serotype A Injections for Cervicobrachial Myofascial Syndrome

Phase 4

Completed

Conditions: Cervicobrachial Neuralgia
Myofascial Pain Syndromes

First Posted Date: 2005-10-18

Last Posted Date: 2016-06-21

Lead Sponsor: University of California, Los Angeles

Target Recruit Count: 132

Registration Number: NCT00241215

Locations: 🇺🇸
UCLA Pain Management Center, Santa Monica, California, United States

Rapamycin vs Methotrexate in Diffuse SSc

Phase 1

Completed

Conditions: Systemic Sclerosis

Interventions: Drug: rapamycin
Drug: methotrexate

First Posted Date: 2005-10-18

Last Posted Date: 2016-04-11

Lead Sponsor: University of California, Los Angeles

Target Recruit Count: 17

Registration Number: NCT00241189

Locations: 🇺🇸
Philip Clements, MD, Los Angeles, California, United States

Long-term Observation of Patients With Early Rheumatoid Arthritis

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2005-10-17

Last Posted Date: 2020-11-17

Lead Sponsor: University of California, Los Angeles

Target Recruit Count: 372

Registration Number: NCT00240136

Locations: 🇺🇸
UCLA, Los Angeles, California, United States

Statin Therapy in Heart Failure: Potential Mechanisms of Benefit

Phase 4

Completed

Conditions: Heart Failure, Congestive

Interventions: Drug: placebo
Drug: atorvastatin

First Posted Date: 2005-10-05

Last Posted Date: 2020-03-20

Lead Sponsor: University of California, Los Angeles

Target Recruit Count: 27

Registration Number: NCT00233480

Locations: 🇺🇸
Ahmanson-UCLA Cardiomyopathy Center, Los Angeles, California, United States

Estrogen and Perimenopausal Depression

Phase 4

Completed

Conditions: Depressive Disorder, Major
Menopause

Interventions: Drug: Estrogen

First Posted Date: 2005-09-29

Last Posted Date: 2020-02-25

Lead Sponsor: University of California, Los Angeles

Target Recruit Count: 17

Registration Number: NCT00229450

Locations: 🇺🇸
UCLA Neuropsychiatric Institute & Hospital, Los Angeles, California, United States

Study of Genetic Differences in People With Depression

Completed

Conditions: Depressive Disorder, Major

First Posted Date: 2005-09-29

Last Posted Date: 2016-11-18

Lead Sponsor: University of California, Los Angeles

Target Recruit Count: 200

Registration Number: NCT00229463

Locations: 🇺🇸
UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles, California, United States

Study of Medication and Placebo Response in Major Depression

Phase 4

Completed

Conditions: Depressive Disorder, Major

First Posted Date: 2005-09-29

Last Posted Date: 2016-11-06

Lead Sponsor: University of California, Los Angeles

Target Recruit Count: 60

Registration Number: NCT00229476

Locations: 🇺🇸
UCLA Neuropsychiatric Institute & Hospital, Los Angeles, California, United States

Evaluation of Depression Symptoms and Brain Activity Associated With Response to Treatment of Depression

Phase 4

Completed

Conditions: Depression

Interventions: Behavioral: Interpersonal Clinical Interaction (ICI)
Drug: Venlafaxine (Effexor), Duloxetine (Cymbalta), Escitalopram (Lexapro)
Other: Placebo

First Posted Date: 2005-09-20

Last Posted Date: 2024-08-13

Lead Sponsor: University of California, Los Angeles

Target Recruit Count: 88

Registration Number: NCT00200902

Locations: 🇺🇸
UCLA Laboratory of Brain, Behavior, and Pharmacology, Los Angeles, California, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy